BIOMAT Database Logo BIOMAT Database Logo

[High dosage and intermediate dosage cytosine arabinoside in the treatment of secondary leukemias]. 1988

T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
Abteilung für Hämatologie und Blutgerinnung, I. Medizinische Universitätsklinik, Wien.

Patients with secondary acute myeloid leukaemia (AML) following treatment with alkylating agents and/or radiation show a poor response to standard induction therapy. Between 1983-1987 8 consecutive patients were treated with high-dose cytosine arabinoside (HD-ARA C; 3 g/sqm twice daily for 6 days) or intermediate-dose cytosine arabinoside (ID-ARA C; 0.5 g/sqm twice daily for 6 days). Complete remission was achieved in 3 patients (HD-ARA C: 2/3l; ID-ARA C: 1/5) and partial remission in 3 patients (ID-ARA C: 3/5). One patient (HD-ARA C) died during prolonged aplasia, one patient (ID-ARA C) proved refractory to treatment. The respective duration of remission in the 3 responsive patients was 3, 7 and 8 months. The probability of survival of the whole group was 50% after 12 months and 25% after 24 months. Our results confirm the efficacy of monotherapy with ARA C in the treatment of secondary AML. Consolidation therapy with ID-ARA C for 4 days seems to prolong remission.

UI MeSH Term Description Entries
D007953 Leukemia, Radiation-Induced Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION. Radiation-Induced Leukemia,Leukemia, Radiation Induced,Leukemias, Radiation-Induced,Radiation Induced Leukemia,Radiation-Induced Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
[Cytosine-arabinoside in the treatment of acute leukemias].
April 1972, Wiener medizinische Wochenschrift (1946),
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
[Cytosine-arabinoside in the treatment of acute myeloblastic leukemias].
March 1971, Minerva medica,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
[Treatment of acute leukemias in the infancy with cytosine arabinoside].
June 1971, Minerva pediatrica,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
[High-dose cytosine arabinoside in the treatment of recurrent or acute refractory myeloid leukemias].
February 1985, Onkologie,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
Treatment of acute nonlymphocytic leukemia in the elderly with intermediate high-dose cytosine arabinoside.
January 1989, Medical and pediatric oncology,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
[Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
June 1971, Wiener klinische Wochenschrift,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome.
January 1992, Hematological oncology,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
[Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
January 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
Experience with intermediate and high dose cytosine arabinoside in refractory acute leukaemia.
August 1983, Onkologie,
T Leitha, and U Jäger, and I Schwarzinger, and P Bettelheim, and W Hinterberger, and E Neumann, and C Korninger, and P A Kyrle, and O Haas, and O Schlappack
Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias.
January 1993, Cancer investigation,
Copied contents to your clipboard!